"COVID-19 Vaccine developer/manufacturer ","Vaccine platform ","Type of candidate vaccine ","Number of doses ","Timing of doses ","Route of Administration ","Clinical Stage ","","","",
"","","","","","","Phase 1 ","Phase 1/2 ","Phase 2 ","Phase 3 ",
"University of Oxford/AstraZeneca ","Non-Replicating Viral Vector ","ChAdox1-S ","1 ","","IM ","","PACTR202006922165132 2020-001072-15 Interim Report ","2020-001228-32 ","ISRCTN89951424 NCT04516746 ",
"CanSino Biological Inc./Beijing Institute of Biotechnology ","Non-Replicating Viral Vector ","Adenovirus Type 5 Vector ","1 ","","IM ","ChiCTR2000030906 Study Report ","","ChiCTR2000031781 Study Report ","NCT04526990 ",
"Gamaleya Research Institute ","Non-Replicating Viral Vector ","Adeno-based (rAd26-S+rAd5-S) ","2 ","0,21 days ","IM ","NCT04436471 NCT04437875 ","","","NCT04530396 ",
"Sinovac ","Inactivated ","Inactivated ","2 ","0, 14 days ","IM ","","NCTO4383574 NCTO4352608 ","","NCT04456595 669/UN6.KEP/EC/2020 ",
"Wuhan Institute of Biological Products/Sinopharm ","Inactivated ","Inactivated ","2 ","0,14 or 0,21 days ","IM ","","ChiCTR2000031809 Interim Report ","","ChiCTR2000034780 ",
"Beijing Institute of Biological Products/Sinopharm ","Inactivated ","Inactivated ","2 ","0,14 or 0,21 days ","IM ","","ChiCTR2000032459 ","","ChiCTR2000034780 ",
"Moderna/NIAID ","RNA ","LNP-encapsulated mRNA ","2 ","O, 28 days ","IM ","NCT04283461 Interim Report ","","NCT04405076 ","NCT04470427 ",
"BioNTech/Fosun Pharma/Pfizer ","RNA ","3 LNP-mRNAs ","2 ","O, 28 days ","IM ","","2020-001038-36 ChiCTR2000034825 Study Report ","","NCT04368728 ",
